An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care, 1998. ,
DOI : 10.2337/diacare.21.12.2140
A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats, Metabolism, vol.38, issue.11, pp.1089-1093, 1989. ,
DOI : 10.1016/0026-0495(89)90045-0
Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat, Diabetes, vol.43, issue.12, pp.1435-1439, 1994. ,
DOI : 10.2337/diab.43.12.1435
Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance, Diabetes, vol.47, issue.3, pp.395-400, 1998. ,
DOI : 10.2337/diabetes.47.3.395
Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM, Diabetes Care, vol.14, issue.11, pp.1083-1086, 1991. ,
DOI : 10.2337/diacare.14.11.1083
Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects, Diabetes Care, vol.15, issue.2, pp.193-203, 1992. ,
DOI : 10.2337/diacare.15.2.193
A Rational Approach to Drug Therapy of Type 2 Diabetes Mellitus, Drugs, vol.6, issue.6285, pp.95-113, 2000. ,
DOI : 10.2337/diacare.20.7.1183
Glitazones and Heart Failure: Critical Appraisal for the Clinician, Circulation, vol.107, issue.10, pp.1350-1354, 2003. ,
DOI : 10.1161/01.CIR.0000054675.30348.9A
Safety profile of pioglitazone, Int J Clin Pract, vol.121, pp.27-31, 2001. ,
Thiazolidinedione-Induced Edema, Pharmacotherapy, vol.49, issue.1, pp.924-933, 2002. ,
DOI : 10.1001/jama.283.13.1695
Pulmonary Edema Associated with Rosiglitazone and Troglitazone, Annals of Pharmacotherapy, vol.159, issue.1, pp.123-127, 2001. ,
DOI : 10.1038/clpt.1981.154
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure, CMAJ, vol.166, issue.2, p.219, 2002. ,
A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes, Diabetes Care, vol.24, issue.7, pp.1226-1258, 2001. ,
DOI : 10.2337/diacare.24.7.1226
Efficacy and safety of pioglitazone in type 2 diabete : a randomized, placebo-controlled study in patients receiving stable insulin therapy, Int J Clin Pract, vol.56, pp.251-258, 2002. ,
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia, Diabetes Care, vol.28, issue.7, pp.1547-1554, 2005. ,
DOI : 10.2337/diacare.28.7.1547
Thiazolidinediones expand body fluid volume through PPAR?? stimulation of ENaC-mediated renal salt absorption, Nature Medicine, vol.6, issue.8, pp.861-867, 2005. ,
DOI : 10.1023/A:1018401015497
Troglitazone Treatment Increases Plasma Vascular Endothelial Growth Factor in Diabetic Patients and Its mRNA in 3T3-L1 Adipocytes, Diabetes, vol.50, issue.5, pp.1166-77, 2001. ,
DOI : 10.2337/diabetes.50.5.1166
URL : http://diabetes.diabetesjournals.org/content/diabetes/50/5/1166.full.pdf
Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?, The American Journal of Cardiology, vol.93, issue.5, pp.600-602, 2004. ,
DOI : 10.1016/j.amjcard.2003.11.025
Approach to the management of diabetic patients with heart failure: Role of thiazolidinediones, American Heart Journal, vol.148, issue.4, pp.551-559, 2004. ,
DOI : 10.1016/j.ahj.2004.04.033
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes ,
Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes, Diabetes, vol.54, p.21, 2005. ,
Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus, JAMA, vol.294, issue.20, pp.2581-2587, 2005. ,
DOI : 10.1001/jama.294.20.joc50147
Lipotoxic heart disease in obese rats: implications for human obesity, Proc Natl Acad Sei, vol.97, pp.1784-1793, 2000. ,
Peroxisome Proliferator-Activated Receptor Activators Inhibit Lipopolysaccharide-Induced Tumor Necrosis Factor-?? Expression in Neonatal Rat Cardiac Myocytes, Circulation Research, vol.87, issue.7, pp.596-602, 2000. ,
DOI : 10.1161/01.RES.87.7.596
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A retrospective cohort study, Diabetes Care, vol.26, issue.11, pp.2983-2992, 2003. ,
DOI : 10.2337/diacare.26.11.2983
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project, Diabetes Care, vol.28, issue.7, pp.1680-1689, 2005. ,
DOI : 10.2337/diacare.28.7.1680
URL : http://care.diabetesjournals.org/content/diacare/28/7/1680.full.pdf
Pioglitazone initiation and subsequent hospitalization for congestive heart failure, Diabetic Medicine, vol.56, issue.8, pp.986-93, 2005. ,
DOI : 10.1056/NEJM199312303292710
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557913/pdf
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study, Circulation, vol.11, pp.583-90, 2005. ,
Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting, Diabetes Care, vol.28, issue.1, pp.20-26, 2005. ,
DOI : 10.2337/diacare.28.1.20
Heart Failure: The frequent, forgotten, and often fatal complication of diabetes, Diabetes Care, vol.26, issue.8, pp.2433-2474, 2003. ,
DOI : 10.2337/diacare.26.8.2433
Diabetes and Cardiovascular Disease, JAMA, vol.241, issue.19, pp.2035-2041, 1979. ,
DOI : 10.1001/jama.1979.03290450033020
Incidence of Heart Failure in 2,737 Older Persons With and Without Diabetes Mellitus, Chest, vol.115, issue.3, pp.867-875, 1999. ,
DOI : 10.1378/chest.115.3.867
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, vol.321, issue.7258, pp.405-412, 2000. ,
DOI : 10.1136/bmj.321.7258.405
Insulin Resistance in Chronic Heart Failure: Relation to Severity and Etiology of Heart Failure, Journal of the American College of Cardiology, vol.30, issue.2, pp.527-559, 1997. ,
DOI : 10.1016/S0735-1097(97)00185-X
Diabetes and Atherosclerosis, JAMA, vol.287, issue.19, pp.2570-81, 2002. ,
DOI : 10.1001/jama.287.19.2570
Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure, Journal of the American College of Cardiology, vol.41, issue.8, pp.1394-1398, 2003. ,
DOI : 10.1016/S0735-1097(03)00159-1
Is the tolerability of long-term thiazolidinedione therapy overstated?, Journal of the American College of Cardiology, vol.42, issue.7, pp.1334-1334, 2003. ,
DOI : 10.1016/S0735-1097(03)00995-1
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, The Lancet, vol.366, issue.9493, pp.1279-89, 2005. ,
DOI : 10.1016/S0140-6736(05)67528-9
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy, New England Journal of Medicine, vol.355, issue.23, pp.2427-2470, 2006. ,
DOI : 10.1056/NEJMoa066224
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose : A randomised controlled trial, Lan cet, vol.368, pp.1096-105, 2006. ,
The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction, Journal of the American College of Cardiology, vol.49, issue.17, pp.1772-80, 2007. ,
DOI : 10.1016/j.jacc.2006.12.048
Thiazolidinediones and Risk of Repeat Target Vessel Revascularization Following Percutaneous Coronary Intervention: A meta-analysis, Diabetes Care, vol.30, issue.2, pp.384-392, 2007. ,
DOI : 10.2337/dc06-1854
Insulin Sensitizing Pharmacotherapy for Prevention of Myocardial Infarction in Patients With Diabetes Mellitus, The American Journal of Cardiology, vol.97, issue.5, pp.651-654, 2006. ,
DOI : 10.1016/j.amjcard.2005.09.106
The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy, Pharmacoepidemiology and Drug Safety, vol.15, issue.5, pp.504-512, 2007. ,
DOI : 10.1093/oxfordjournals.aje.a010011
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes, New England Journal of Medicine, vol.356, issue.24, pp.2457-71, 2007. ,
DOI : 10.1056/NEJMoa072761
Rosiglitazone and Cardiovascular Risk, New England Journal of Medicine, vol.356, issue.24, pp.2522-2526, 2007. ,
DOI : 10.1056/NEJMe078099
Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus, JAMA, vol.298, issue.10, pp.1180-1188, 2007. ,
DOI : 10.1001/jama.298.10.1180
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity : a review. Drng metab pharmacokinet 2006 oct, pp.347-56 ,
DOI : 10.2133/dmpk.21.347
Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction, Diabetes Care, vol.25, issue.5, pp.815-836, 2002. ,
DOI : 10.2337/diacare.25.5.815
Thiazolidinediones and liver toxicity. Diabetes Metab, 2001. ,
Mixed Hepatocellular???Cholestatic Liver Injury after Pioglitazone Therapy, Annals of Internal Medicine, vol.136, issue.6, pp.449-52, 2002. ,
DOI : 10.7326/0003-4819-136-6-200203190-00008
Hepatocellular Injury in a Patient Receiving Pioglitazone, Annals of Internal Medicine, vol.135, issue.4, p.306, 200121. ,
DOI : 10.7326/0003-4819-135-4-200108210-00029
URL : http://annals.org/data/journals/aim/19989/0000605-200108210-00015.pdf
Severe but Reversible Cholestatic Liver Injury after Pioglitazone Therapy, Annals of Internal Medicine, vol.137, issue.10, p.857, 2002. ,
DOI : 10.7326/0003-4819-137-10-200211190-00023
Pioglitazone-associated fulminant hepatic failure, The American Journal of Gastroenterology, vol.132, issue.2, pp.502-505, 2002. ,
DOI : 10.1111/j.1572-0241.2000.01707.x
Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone, Digestive Diseases and Sciences, vol.47, issue.7, pp.1632-1639, 2002. ,
DOI : 10.1023/A:1015895925374
Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report, Annals of Internal Medicine, vol.132, issue.2, pp.121-125, 2000. ,
DOI : 10.7326/0003-4819-132-2-200001180-00006
Hepatic Failure in a Patient Taking Rosiglitazone, Annals of Internal Medicine, vol.132, issue.2, pp.118-139, 2000. ,
DOI : 10.7326/0003-4819-132-2-200001180-00005
Comparaison of pioglitazone with other antidiabetic dugs for associated incidence of liver failure : no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab, pp.161-170, 2005. ,
Hepatotoxicity with Thiazolidinediones, Drug Safety, vol.22, issue.7, pp.873-88, 2001. ,
DOI : 10.2165/00002018-200124120-00002
Use of prop011ional reporting ratios (PRRs) for signal generation frorn spontaneous adverse drug reaction reports ,
Detecting drugdrug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs, Eur J Clin Pharmacol, vol.56, pp.9-10733, 2000. ,
Materna! valproic acid and congenital neural tube defects, Lancet, vol.2, p.937, 1982. ,
Serum sickness-like reactions to cefaclor, Journal of Clinical Epidemiology, vol.45, issue.10, pp.1177-1184, 1992. ,
DOI : 10.1016/0895-4356(92)90158-J
Hyponatremia m relation to treatment with antidepressants : a survey of reports in the World Health Organisation . Database for spontaneous reporting of adverse drug reactions, Pharmacotherapy, vol.17, pp.348-352, 1997. ,
Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986???2001), Drug Safety, vol.46, issue.8, pp.731-771, 1986. ,
DOI : 10.2165/00002018-200528080-00007
URL : https://hal.archives-ouvertes.fr/hal-00396045
Risk of Serious Extrapyramidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs, Clinical Neuropharmacology, vol.26, issue.3, pp.142-147, 2003. ,
DOI : 10.1097/00002826-200305000-00007
Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients, Eur J Clin Pharmacol, vol.62, issue.3, pp.243-252, 2006. ,
Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database, British Journal of Clinical Pharmacology, vol.44, issue.5, pp.513-521, 1997. ,
DOI : 10.1046/j.1365-2125.1997.00615.x
Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure, Epidemiology, vol.14, issue.2, pp.240-246, 2003. ,
Metformin in Heart Failure, Diabetes Care, vol.30, issue.12, pp.2585-2592, 2005. ,
DOI : 10.2337/dc07-1686
Obesity and the Risk of Heart Failure, New England Journal of Medicine, vol.347, issue.5, pp.305-318, 2002. ,
DOI : 10.1056/NEJMoa020245
Do thiazolidinediones cause heart failure? A critical review., Cleveland Clinic Journal of Medicine, vol.73, issue.4, pp.390-397, 2006. ,
DOI : 10.3949/ccjm.73.4.390
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, vol.16, issue.2, pp.434-478, 1993. ,
DOI : 10.2337/diacare.16.2.434
Nonsteroidal anti-inflammatory drug-induced hepatotoxicity.Clin Liver Dis, pp.563-75, 2007. ,
DOI : 10.1016/j.cld.2007.06.004
Accréditation et d'Evaluation en Santé, 2003. ,
Données épidémiologiques sur le diabète de type 2, BEH, pp.20-21, 2002. ,
Données actualisées de l'UKPDS ; implication pour la prise en charge des patients diabétiques de type 2, MT Endocrinologie, vol.3, pp.207-216, 2000. ,
Prevalence of diabetes in france and Drug use: Study based on the French Pharmacovigilance Database. Therapie, Novembre-Decembre, vol.62, issue.6, pp.483-488, 2007. ,
Assessing the prevalence of adverse drug reactions in a French University Hospital: a capturerecapture study using data from PMSI and the French pharmacovigilance database ,
Drug safety of Thiazolidinediones in France. Fundamental & Clinical Pharmacology. Abstracts of the P2T Congres de Physiologie, Annexe, vol.1, issue.22, pp.1-102, 2008. ,
Prevalence of diabetes in france and Drug use: Study based on the French Pharmacovigilance Database. Therapie, Novembre-Decembre, vol.62, issue.6, pp.483-488, 2007. ,